Alnylam Receives Allowance for Broad New European Patent Covering RNAi Therapeutics
New "Kreutzer-Limmer II'' Patent Covers RNAi Therapeutics towards over 125 Disease Targets
Advertisement
Alnylam Pharmaceuticals, Inc. announced the allowance of broad claims from the European Patent Office for a new patent (EP Patent No. 1352061) covering small interfering RNAs (siRNAs), the molecules that mediate RNA interference (RNAi). The new "Kreutzer-Limmer II" patent, which Alnylam acquired in the July 2003 merger with Ribopharma AG, includes allowed claims that cover therapeutic compositions, methods, and uses of siRNAs and derivatives directed toward over 125 disease targets.
The new patent includes 103 allowed claims on therapeutic compositions, methods, and uses comprising siRNAs that are complementary to all mRNA sequences in over 125 disease target genes. These genes include targets that are part of ongoing Alnylam development and pre-clinical programs, such as those involved in the VEGF pathway and those expressed by viral pathogens including RSV and influenza virus. In addition, the claimed targets include oncogenes, cytokines, cell adhesion receptors, angiogenesis targets, apoptosis and cell cycle targets, and additional viral disease targets such as HCV and HIV.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome - Results Presented at American College of Gastroenterology Annual Meeting Show Majority of Responders Continued to Benefit from GATTEX in Phase 3-Extension Study
Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million - "This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"
Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe
Risk of lead poisoning from urban gardening is low, new study finds
World first: Launch of Quebec registry for users of medical cannabis - MUHC researcher heads one of the largest studies ever conducted on medical cannabis
Implant-based cancer vaccine is first to eliminate tumors in mice - New approach reprograms the mammalian immune system to attack tumors body-wide
Study IDs link between sugar signaling and regulation of oil production in plants
It all adds up: Study finds forever chemicals are more toxic as mixtures - Research also finds that PFOA and PFOS are major contributors to toxicity
Affibody to publish data on therapeutic effects of Affibody molecules in a cancer model
‘Seaweed drug’ helps fight off infection - Alginates found in seaweed can combat multi-drug resistant infections
Antibiotic-releasing polymer may help eradicate joint implant infection
